

Lot No.: **0F2**

Lot-specific information

Olerup SSP[®] HLA-C*04

Product number:	101.612-12 – including <i>Taq</i> polymerase 101.612-12u – without <i>Taq</i> polymerase
Lot number:	0F2
Expiry date:	2019-11-01
Number of tests:	12
Number of wells per test:	63+1
Storage - pre-aliquoted primers:	dark at -20°C
- PCR Master Mix:	-20°C
- Adhesive PCR seals	RT
- Product Insert	RT

This Product Description is only valid for Lot No. 0F2.

Complete product documentation consists of generic Instructions for Use (IFU), lot specific Product Insert, Worksheet and Certificate.

**CHANGES COMPARED TO THE PREVIOUS OLERUP SSP[®]
HLA-C*04 LOT (5D7)**

The HLA-C*04 kit is updated for new alleles to enable separation of:

- Confirmed¹ alleles as listed in the IMGT/HLA database
- Polymorphisms in exons outside of the region encoding the peptide binding domain
- Null and Alternatively expressed alleles

The format of the Worksheet has been changed.

Four wells have been added to HLA-C*04, wells **61 to 64**.

¹As described in section Uniquely Identified Alleles.

The HLA-C*04 primer set, specificity and interpretation tables have been updated for the HLA-C alleles described since the previous *Olerup SSP[®]* HLA-C*04 lot was made (**Lot No. 5D7**). The kit design is based on IMGT/HLA database 3.26.0.

Lot No.: 0F2

Lot-specific information

The primers of the wells detailed below have been exchanged, added or modified compared to the previous lot.

Well	5'-primer	3'-primer	rationale
1	-	Modified	3'-primer modified for improved HLA-specific amplification.
4	Modified	-	5'-primer modified for improved HLA-specific amplification.
11	Added	-	5'-primer added for the C*04:01:74 allele.
13	-	Added	3'-primer added for the C*04:255N allele.
14	-	Added	3'-primer added for the C*04:223:01 allele.
17	Added	-	5'-primer added for the C*04:234N allele.
19	Added	-	5'-primer added for the C*04:238 allele, 5'-primer added from well 23.
20	-	Added	3'-primer added for the C*04:209 allele.
21	-	Added	3'-primer added for the C*04:218 allele. Exchanged of positive control primer pairs.
22	Added	-	5'-primer added for the C*04:226 allele.
23	Moved	-	5'-primers moved to wells 19 and 44 for improved HLA-specific amplification.
24	Added	-	5'-primer added for increased allelic resolution of the C*04:24 allele.
26	-	Added	3'-primer added for the C*04:250 allele.
27	-	Added	3'-primer added for the C*04:204 allele.
28	-	Added	3'-primers added for the C*04:204 and C*04:223:01 alleles.
29	-	Added	3'-primer added for the C*04:249 allele.
30	Added	-	5'-primer added for the C*04:234N allele.
31	Added	-	5'-primer added for the C*04:226 allele.
32	-	Added	3'-primer added for the C*04:141 allele.
33	-	Modified, added	3'-primers modified for improved HLA-specific amplification, 3'-primer added for the C*04:218 allele.
34	-	Added	3'-primers added for the C*04:201 and C*04:253N alleles
35	-	Added	3'-primers added for the C*04:255N allele.
36	-	-	Exchanged positive control primer pairs for decreased tendency of primer oligomer formation.
38	-	-	Exchanged positive control primer pairs for improved HLA-specific amplification.
40	-	Added	3'-primer added for the C*04:201 allele.
43	-	Added	3'-primer added for the C*04:209 allele.
44	Added	-	5'-primer added for the C*04:254 allele, 5'-primer added from well 23.
45	Added	-	5'-primer added for the C*04:233N allele.

Lot No.: 0F2

Lot-specific information

46	Added	-	5'-primers added for the C*04:187 and C*04:254 alleles.
48	-	Exchanged	3'-primer exchanged for improved HLA-specific amplification.
49	-	Added	3'-primer added for the C*04:225N allele.
51	Added	-	5'-primer added from well 56.
53	-	Exchanged	3'-primer and positive control primer pairs exchanged for decreased tendency of primer oligomer formation.
54	-	Added	3'-primers added for the C*04:219 and C*04:249 alleles.
55	-	Added	3'-primers added for the C*04:225N and C*04:250 alleles.
56	Moved	Exchanged	5'-primer moved to well 51 and 3'-primer exchanged for improved HLA-specific amplification.
57	Added	-	5'-primer added for the C*04:233N allele.
59	-	-	Exchanged positive control primer pairs for improved HLA-specific amplification.
60	Added	Added	Negative Control moved to well 64, primer pair added for improved allelic resolution.
61	New	New	New primer pairs added for the C*04:206 and C*04:236N alleles.
62	New	New	New primer pairs added for the C*04:141 and C*04:253N alleles.
63	New	New	New primer pair added for the C*04:180:01-04:180:02 alleles.
64	-	-	Negative control added from well 60.

Changes in revision R01 compared to R00:

1. Primer mix 51 does not amplify the C*04:165 allele. This has been corrected in the Specificity and Interpretation Tables.

Change in revision R02 compared to R01:

1. Primer mix 16 does not amplify the C*04:15:02 and 04:17 and the C*03:13:01, 03:35:01, 03:198, 08:01:07, 08:02:07 and 08:33:02 alleles. Thus, this lot of the C*04 subtyping kit cannot distinguish the C*04:15:02 and the C*04:224 and 04:230 alleles, or the C*04:17 and C*04:100 alleles. This has been corrected in the Specificity and Interpretation Tables.

101.612-12 – including *Taq* pol., IFU-01

101.612-12u – without *Taq* pol., IFU-02

Visit www.olerup.com for
“Instructions for Use” (IFU)

Lot No.: **0F2**

Lot-specific information

Well **64** contains Negative Control primer pairs, that will amplify more than 95% of the *Olerup SSP*[®] HLA Class I, DRB, DQB1, DPB1 and DQA1 amplicons as well as all the amplicons generated by the control primer pairs matching the human growth hormone gene.

HLA-specific PCR product sizes range from 75 to 200 base pairs.

The PCR product generated by the positive control primer pair is 430 base pairs.

Length of PCR product	105	200	105	80	75	80	85
5'-primer¹	164	340	440	45	45	43	36
	5'-CAC ^{3'}	5'-Agg ^{3'}	5'-TTA ^{3'}	5'-Tgg ^{3'}	5'-Tgg ^{3'}	5'-Tgg ^{3'}	5'-TAC ^{3'}
							36
							5'-TAT ^{3'}
3'-primer²	231	2nd I	507	59	58	57	47
	5'-TgC ^{3'}	5'-AAA ^{3'}	5'-TTg ^{3'}	5'-CTC ^{3'}	5'-ggC ^{3'}	5'-CTC ^{3'}	5'-ACA ^{3'}
							48
							5'-gCA ^{3'}
							48
							5'-gCC ^{3'}
							52
							5'-TgT ^{3'}
A*	+	+	+				
B*	+	+	+				
C*	+	+	+				
DRB1				+	+		
DRB3				+	+		
DRB5				+			
DQB1					+		
DPB1						+	
DQA1							+

¹The nucleotide position for HLA class I genes and the codon for HLA class II genes, in the 2nd or 3rd exon, matching the specificity-determining 3'-end of the primer is given. Nucleotide and codon numbering as on the www.ebi.ac.uk/imgt/hla web site. The sequence of the 3 terminal nucleotides of the primer is given.

²The nucleotide position for HLA class I genes and the codon for HLA class II genes, in the 2nd or 3rd exon or the 2nd intron, matching the specificity-determining 3'-end of the primer is given in the anti-sense direction. Nucleotide and codon numbering as on the www.ebi.ac.uk/imgt/hla web site. The sequence of the 3 terminal nucleotides of the primer is given.

101.612-12 – including *Taq* pol., IFU-01
101.612-12u – without *Taq* pol., IFU-02

Visit www.olerup.com for
“Instructions for Use” (IFU)

Lot No.: **0F2**

Lot-specific information

PRODUCT DESCRIPTION

HLA-C*04 SSP subtyping

CONTENT

The primer set contains 5'- and 3'-primers for identifying the HLA-C*04:01 to HLA-C*04:257 alleles.

PLATE LAYOUT

Each test consists of 64 PCR reactions in a 64 well PCR plate.

1	2	3	4	5	6	7	8
9	10	11	12	13	14	15	16
17	18	19	20	21	22	23	24
25	26	27	28	29	30	31	32
33	34	35	36	37	38	39	40
41	42	43	44	45	46	47	48
49	50	51	52	53	54	55	56
57	58	59	60	61	62	63	NC

The 64 well cut PCR plate is marked with 'HLA-C*04' in silver/gray ink.

Well No. 1 is marked with the Lot No. '0F2'.

Wells 1 to 63 – HLA-C*04 high resolution primers.

Well 64 – Negative Control (NC).

A faint row of numbers is seen between wells 1 and 2 or wells 7 and 8 of the PCR trays. These stem from the manufacture of the trays, and should be disregarded. The PCR plates are heat-sealed with a PCR-compatible foil.

INTERPRETATION

Due to the sharing of sequence motifs between HLA-C alleles non-HLA-C*04 alleles will be amplified by some primer mixes. For further details see Specificity Table.

UNIQUELY IDENTIFIED ALLELES

All the HLA-C*04 alleles, i.e. **C*04:01 to C*04:257**, recognized by the HLA Nomenclature Committee in October 2016^{1,2} will be amplified by the primers in the HLA-C*04 kit³.

The HLA-C*04 kit enables separation of the confirmed HLA-C*04 alleles as listed in the IMGT/HLA database. An HLA allele is listed as confirmed by IMGT/HLA if it has been sequenced by more than a single laboratory or from multiple sources. Current allele confirmation status for HLA-C*04 alleles is listed below.

The HLA-C*04 kit also enables identification of polymorphisms in exons outside of the region encoding the peptide binding domain and of null and alternatively expressed alleles.

101.612-12 – including *Taq* pol., IFU-01
101.612-12u – without *Taq* pol., IFU-02

Visit www.olerup.com for
“Instructions for Use” (IFU)

Lot No.: 0F2

Lot-specific information

The following HLA-C*04 alleles can be distinguished by the different sizes of the HLA-specific PCR product:

Alleles	Primer mix	Alleles	Primer mix
C*04:05, 04:112	6	C*04:61, 04:96	34
C*04:20, 04:238	19	C*04:62, 04:76	35
C*04:23, 04:38, 04:39	21	C*04:65, 04:72	33
C*04:25, 04:41	23	C*04:67, 04:93N, 04:187	46
C*04:44, 04:47	20	C*04:79, 04:113	39
C*04:46, 04:50	27	C*04:81, 04:88N	43
C*04:54, 04:105N	41	C*04:114, 04:146	47
C*04:56, 04:64:01-04:64:02	40	C*04:139, 04:226	22
C*04:59Q, 04:78	32	C*04:150, 04:155	52

¹HLA-C alleles listed on the IMGT/HLA web page 2016-October-14, release 3.26.0, www.ebi.ac.uk/imgt/hla.

²Alleles that have been deleted from or renamed in the official WHO HLA Nomenclature up to and including the last IMGT/HLA database release can be retrieved from web page <http://hla.alleles.org/alleles/deleted.html>.

³This lot of the C*04 subtyping kit cannot distinguish the C*04:15:02 and the C*04:224 and 04:230 alleles, or the C*04:17 and C*04:100 alleles

101.612-12 – including *Taq* pol., IFU-01
101.612-12u – without *Taq* pol., IFU-02

Visit www.olerup.com for
“Instructions for Use” (IFU)

Lot No.: **0F2**

Lot-specific information

ALLELE CONFIRMATION STATUS

Allele	Status ¹	Allele	Status ¹	Allele	Status ¹	Allele	Status ¹
C*04:01:01:01	Confirmed	C*04:01:45	Unconfirmed	C*04:15:01	Unconfirmed	C*04:64:01	Unconfirmed
C*04:01:01:02	Unconfirmed	C*04:01:46	Confirmed	C*04:15:02	Confirmed	C*04:64:02	Unconfirmed
C*04:01:01:03	Unconfirmed	C*04:01:47	Unconfirmed	C*04:15:03	Unconfirmed	C*04:65	Confirmed
C*04:01:01:04	Unconfirmed	C*04:01:48	Unconfirmed	C*04:16	Confirmed	C*04:66	Unconfirmed
C*04:01:01:05	Confirmed	C*04:01:49	Unconfirmed	C*04:17	Unconfirmed	C*04:67	Unconfirmed
C*04:01:01:06	Confirmed	C*04:01:50	Unconfirmed	C*04:18	Unconfirmed	C*04:68	Confirmed
C*04:01:01:07	Unconfirmed	C*04:01:51	Unconfirmed	C*04:19	Confirmed	C*04:69	Confirmed
C*04:01:02	Unconfirmed	C*04:01:52	Unconfirmed	C*04:20	Unconfirmed	C*04:70	Unconfirmed
C*04:01:03	Unconfirmed	C*04:01:53	Unconfirmed	C*04:23	Confirmed	C*04:71	Unconfirmed
C*04:01:04	Confirmed	C*04:01:54	Unconfirmed	C*04:24	Unconfirmed	C*04:72	Confirmed
C*04:01:05	Unconfirmed	C*04:01:55	Unconfirmed	C*04:25	Unconfirmed	C*04:73	Unconfirmed
C*04:01:06	Unconfirmed	C*04:01:56	Confirmed	C*04:26	Confirmed	C*04:74	Confirmed
C*04:01:07	Unconfirmed	C*04:01:57	Unconfirmed	C*04:27	Confirmed	C*04:75	Confirmed
C*04:01:08	Confirmed	C*04:01:58	Unconfirmed	C*04:28	Unconfirmed	C*04:76	Unconfirmed
C*04:01:09	Confirmed	C*04:01:59	Unconfirmed	C*04:29	Confirmed	C*04:77	Confirmed
C*04:01:10	Confirmed	C*04:01:60	Unconfirmed	C*04:30	Unconfirmed	C*04:78	Unconfirmed
C*04:01:11	Confirmed	C*04:01:61	Unconfirmed	C*04:31	Unconfirmed	C*04:79	Unconfirmed
C*04:01:12	Confirmed	C*04:01:62	Confirmed	C*04:32	Confirmed	C*04:80	Unconfirmed
C*04:01:13	Confirmed	C*04:01:63	Unconfirmed	C*04:33	Confirmed	C*04:81	Confirmed
C*04:01:14	Confirmed	C*04:01:64	Unconfirmed	C*04:34	Unconfirmed	C*04:82	Confirmed
C*04:01:15	Confirmed	C*04:01:65	Unconfirmed	C*04:35	Unconfirmed	C*04:83	Confirmed
C*04:01:16	Confirmed	C*04:01:66	Unconfirmed	C*04:36	Confirmed	C*04:84	Unconfirmed
C*04:01:17	Unconfirmed	C*04:01:67	Unconfirmed	C*04:37	Confirmed	C*04:85	Unconfirmed
C*04:01:18	Unconfirmed	C*04:01:68	Unconfirmed	C*04:38	Confirmed	C*04:86	Confirmed
C*04:01:19	Unconfirmed	C*04:01:69	Unconfirmed	C*04:39	Confirmed	C*04:87	Unconfirmed
C*04:01:20	Unconfirmed	C*04:01:70	Confirmed	C*04:40	Confirmed	C*04:88N	Unconfirmed
C*04:01:21	Confirmed	C*04:01:71	Unconfirmed	C*04:41	Unconfirmed	C*04:89	Unconfirmed
C*04:01:22	Unconfirmed	C*04:01:72	Unconfirmed	C*04:42:01	Confirmed	C*04:90	Unconfirmed
C*04:01:23	Unconfirmed	C*04:01:73	Unconfirmed	C*04:42:02	Confirmed	C*04:91	Confirmed
C*04:01:24	Unconfirmed	C*04:01:74	Unconfirmed	C*04:43	Confirmed	C*04:92	Unconfirmed
C*04:01:25	Unconfirmed	C*04:01:75	Unconfirmed	C*04:44	Unconfirmed	C*04:93N	Confirmed
C*04:01:26	Unconfirmed	C*04:01:76	Unconfirmed	C*04:45	Confirmed	C*04:94:01	Confirmed
C*04:01:27	Unconfirmed	C*04:01:79	Unconfirmed	C*04:46	Confirmed	C*04:94:02	Unconfirmed
C*04:01:28	Confirmed	C*04:01:80	Unconfirmed	C*04:47	Confirmed	C*04:95N	Unconfirmed
C*04:01:29	Unconfirmed	C*04:01:81	Unconfirmed	C*04:48	Confirmed	C*04:96	Confirmed
C*04:01:30	Confirmed	C*04:03:01	Confirmed	C*04:49	Confirmed	C*04:97	Unconfirmed
C*04:01:31	Unconfirmed	C*04:03:02	Unconfirmed	C*04:50	Unconfirmed	C*04:98:01	Unconfirmed
C*04:01:32	Unconfirmed	C*04:03:03	Unconfirmed	C*04:51	Unconfirmed	C*04:98:02	Unconfirmed
C*04:01:33	Confirmed	C*04:04:01	Confirmed	C*04:52	Confirmed	C*04:99	Unconfirmed
C*04:01:34	Unconfirmed	C*04:04:02	Unconfirmed	C*04:53	Unconfirmed	C*04:100	Unconfirmed
C*04:01:35	Unconfirmed	C*04:05	Unconfirmed	C*04:54	Confirmed	C*04:101	Unconfirmed
C*04:01:36	Unconfirmed	C*04:06	Confirmed	C*04:55	Unconfirmed	C*04:102	Unconfirmed
C*04:01:37	Unconfirmed	C*04:07	Confirmed	C*04:56	Confirmed	C*04:103	Confirmed
C*04:01:38	Unconfirmed	C*04:08	Confirmed	C*04:57	Unconfirmed	C*04:104	Unconfirmed
C*04:01:39	Unconfirmed	C*04:09N	Confirmed	C*04:58	Confirmed	C*04:105N	Unconfirmed
C*04:01:40	Unconfirmed	C*04:10	Confirmed	C*04:59Q	Confirmed	C*04:106	Unconfirmed
C*04:01:41	Unconfirmed	C*04:11	Confirmed	C*04:60	Unconfirmed	C*04:107	Unconfirmed
C*04:01:42	Unconfirmed	C*04:12	Unconfirmed	C*04:61	Confirmed	C*04:108	Confirmed
C*04:01:43	Unconfirmed	C*04:13	Confirmed	C*04:62	Confirmed	C*04:109	Unconfirmed
C*04:01:44	Confirmed	C*04:14	Confirmed	C*04:63	Confirmed	C*04:110	Unconfirmed

101.612-12 – including **Taq pol.**, IFU-01
101.612-12u – without **Taq pol.**, IFU-02

Visit www.olerup.com for
“Instructions for Use” (IFU)

Lot No.: **0F2**

Lot-specific information

Allele	Status ¹	Allele	Status ¹	Allele	Status ¹	Allele	Status ¹
C*04:111	Unconfirmed	C*04:151	Unconfirmed	C*04:190	Unconfirmed	C*04:229	Unconfirmed
C*04:112	Confirmed	C*04:152	Unconfirmed	C*04:191N	Unconfirmed	C*04:230	Unconfirmed
C*04:113	Confirmed	C*04:153	Confirmed	C*04:192	Unconfirmed	C*04:231	Unconfirmed
C*04:114	Confirmed	C*04:154	Unconfirmed	C*04:193	Unconfirmed	C*04:232	Unconfirmed
C*04:115N	Unconfirmed	C*04:155	Confirmed	C*04:194	Unconfirmed	C*04:233N	Unconfirmed
C*04:116	Unconfirmed	C*04:156	Unconfirmed	C*04:195	Confirmed	C*04:234N	Unconfirmed
C*04:117	Confirmed	C*04:157	Unconfirmed	C*04:196	Unconfirmed	C*04:235	Unconfirmed
C*04:118	Unconfirmed	C*04:158	Unconfirmed	C*04:197	Unconfirmed	C*04:236N	Unconfirmed
C*04:119	Unconfirmed	C*04:159	Unconfirmed	C*04:198	Unconfirmed	C*04:237	Unconfirmed
C*04:120	Confirmed	C*04:160	Unconfirmed	C*04:199	Unconfirmed	C*04:238	Confirmed
C*04:121	Confirmed	C*04:161	Unconfirmed	C*04:200	Unconfirmed	C*04:239	Unconfirmed
C*04:122	Unconfirmed	C*04:162	Unconfirmed	C*04:201	Confirmed	C*04:240	Unconfirmed
C*04:123N	Unconfirmed	C*04:163	Confirmed	C*04:202	Confirmed	C*04:241	Unconfirmed
C*04:124	Unconfirmed	C*04:164	Unconfirmed	C*04:203N	Unconfirmed	C*04:242	Unconfirmed
C*04:125	Confirmed	C*04:165	Unconfirmed	C*04:204	Unconfirmed	C*04:243	Unconfirmed
C*04:126	Unconfirmed	C*04:166	Confirmed	C*04:205N	Unconfirmed	C*04:244	Unconfirmed
C*04:127	Unconfirmed	C*04:167	Unconfirmed	C*04:206	Confirmed	C*04:245	Unconfirmed
C*04:128	Unconfirmed	C*04:168	Unconfirmed	C*04:207	Confirmed	C*04:246	Unconfirmed
C*04:129	Unconfirmed	C*04:169	Unconfirmed	C*04:208	Unconfirmed	C*04:247	Unconfirmed
C*04:130	Unconfirmed	C*04:170N	Unconfirmed	C*04:209	Confirmed	C*04:248	Unconfirmed
C*04:131	Confirmed	C*04:171	Unconfirmed	C*04:210	Unconfirmed	C*04:249	Unconfirmed
C*04:132	Confirmed	C*04:172	Unconfirmed	C*04:211	Unconfirmed	C*04:250	Confirmed
C*04:133	Unconfirmed	C*04:173N	Unconfirmed	C*04:212	Unconfirmed	C*04:251	Unconfirmed
C*04:134	Unconfirmed	C*04:174	Unconfirmed	C*04:213	Unconfirmed	C*04:252	Unconfirmed
C*04:135	Unconfirmed	C*04:175	Unconfirmed	C*04:214	Unconfirmed	C*04:253N	Unconfirmed
C*04:136	Unconfirmed	C*04:176	Unconfirmed	C*04:215N	Unconfirmed	C*04:254	Confirmed
C*04:137	Confirmed	C*04:177	Unconfirmed	C*04:216	Unconfirmed	C*04:255N	Unconfirmed
C*04:138	Unconfirmed	C*04:178	Unconfirmed	C*04:217N	Unconfirmed	C*04:256	Unconfirmed
C*04:139	Confirmed	C*04:179	Unconfirmed	C*04:218	Confirmed	C*04:257	Unconfirmed
C*04:140	Confirmed	C*04:180:01	Confirmed	C*04:219	Confirmed		
C*04:141	Confirmed	C*04:180:02	Confirmed	C*04:220	Unconfirmed		
C*04:142	Unconfirmed	C*04:181	Unconfirmed	C*04:221	Unconfirmed		
C*04:143	Unconfirmed	C*04:182	Confirmed	C*04:222	Unconfirmed		
C*04:144	Confirmed	C*04:183	Unconfirmed	C*04:223:01	Confirmed		
C*04:145	Confirmed	C*04:184	Unconfirmed	C*04:223:02	Unconfirmed		
C*04:146	Unconfirmed	C*04:185	Unconfirmed	C*04:224	Unconfirmed		
C*04:147	Unconfirmed	C*04:186	Unconfirmed	C*04:225N	Unconfirmed		
C*04:148	Unconfirmed	C*04:187	Confirmed	C*04:226	Unconfirmed		
C*04:149	Unconfirmed	C*04:188	Unconfirmed	C*04:227	Unconfirmed		
C*04:150	Confirmed	C*04:189	Unconfirmed	C*04:228	Unconfirmed		

¹Allele status “confirmed” or “unconfirmed” as listed on the IMGT/HLA web page 2016-October-14, release 3.26.0, www.ebi.ac.uk/imgt/hla.

RESOLUTION IN HOMO- AND HETEROZYGOTES

Results file with resolution in HLA-C*04 homo- and heterozygotes is available upon request.



101.612-12 – including *Taq* pol., IFU-01
101.612-12u – without *Taq* pol., IFU-02

Visit www.olerup.com for
“Instructions for Use” (IFU)

Lot No.: **0F2**

Lot-specific information
SPECIFICITY TABLE

HLA-C*04 SSP subtyping

Specificities and sizes of the PCR products of the 63+1 primer mixes used for
HLA-C*04 SSP subtyping

Primer Mix	Size of spec. PCR product ¹	Size of control band ²	Amplified HLA-C*04 alleles ³	Other amplified HLA Class I alleles
1	250 bp	800 bp	*04:01:01:01-04:01:33, 04:01:34 ^w , 04:01:35-04:01:76, 04:01:79-04:01:81, 04:03:01-04:03:03, 04:05, 04:07-04:12, 04:15:01-04:18, 04:19 ^w , 04:20, 04:23-04:33, 04:35-04:47, 04:48 ^w , 04:49-04:57, 04:59Q-04:67, 04:69-04:94:02, 04:95N ^w , 04:96-04:110, 04:112-04:121, 04:123N-04:159, 04:161-04:177, 04:179-04:187, 04:189-04:211, 04:213-04:256, 04:257 ^w	*01:02:01-01:07:01, 01:08-01:21, 01:23-01:34, 01:36-01:126, 01:128-01:130, 02:02:01-02:02:03, 02:02:05-02:02:32, 02:04-02:15, 02:17, 02:19-02:40:02, 02:42-02:71, 02:73-02:126, 05:01:01:01-05:01:34, 05:03-05:10, 05:12-05:16, 05:18:01-05:26, 05:28-05:50, 05:52-05:61, 05:63-05:67, 05:69, 05:71-05:78:02, 05:80-05:111, 05:113N-05:114, 05:116-05:133, 05:135-05:144, 06:02:01:01-06:02:01:03, 06:02:03-06:03:02, 06:05-06:39, 06:41-06:78, 06:80-06:117, 06:119-06:152N, 06:154-06:196, 08:02:01:01-08:02:14, 08:05, 08:07, 08:12, 08:15:01-08:15:02, 08:17-08:19, 08:23, 08:25, 08:27-08:35, 08:37, 08:43, 08:45, 08:47-08:49, 08:51-08:53, 08:55N, 08:62-08:63, 08:67-08:71, 08:73-08:77, 08:90, 08:92, 08:94, 08:100, 08:103, 08:107-08:108, 08:110-08:112, 08:114-08:116, 08:118, 08:120, 08:123, 08:125-08:126, 08:132, 08:134, 08:140, 12:02:01-12:13, 12:15-12:17, 12:21-12:82, 12:84N-12:136, 12:138-12:152, 12:154-12:168, 12:170-12:174, 12:176-12:180, 12:182-12:200, 14:02:01:01-14:05, 14:07N-14:14, 14:16-14:52, 14:54-14:62, 14:64-14:76, 14:78-14:81, 15:08, 15:74, 15:102, 16:04:01, 16:04:03-16:04:04, 16:29, 16:33, 16:42, 16:53, 16:55, 16:61, 16:66, 16:68, 16:78, 16:82, 16:88, 16:91, 17:17, 18:01-18:10
2	220 bp	1070 bp	*04:01:01:01-04:01:27, 04:01:29-04:01:76, 04:01:79-04:01:81, 04:04:01-04:05, 04:07-04:09N, 04:13-04:15:03, 04:17-04:20, 04:23-04:35, 04:37-04:41, 04:43-04:54, 04:56-04:70, 04:72-04:79, 04:81-04:102, 04:104-04:106, 04:108-04:139, 04:141-04:146, 04:148-04:152, 04:154-04:159, 04:161-04:168, 04:170N, 04:172-04:189, 04:191N, 04:193, 04:195, 04:197-04:209,	*07:64, 07:402

101.612-12 – including *Taq* pol., IFU-01
101.612-12u – without *Taq* pol., IFU-02

Visit www.olerup.com for
“Instructions for Use” (IFU)

Lot No.: **0F2**

Lot-specific information

			04:211-04:212, 04:216-04:219, 04:221-04:226, 04:228-04:248, 04:250-04:255N, 04:257	
3	150 bp	1070 bp	*04:01:01:01-04:01:76, 04:01:79-04:01:81, 04:04:01-04:05, 04:08-04:15:03, 04:17-04:20, 04:23-04:26, 04:28-04:41, 04:43-04:79, 04:81-04:86, 04:88N, 04:90-04:102, 04:104-04:106, 04:108-04:139, 04:141-04:146, 04:148-04:152, 04:154-04:156, 04:158, 04:161-04:170N, 04:172-04:189, 04:191N-04:195, 04:197-04:212, 04:214-04:215N, 04:217N-04:219, 04:221-04:235, 04:237-04:255N, 04:257	*03:231
4	210 bp	1070 bp	*04:03:01-04:03:03, 04:06, 04:80, 04:107, 04:147, 04:160, 04:171, 04:190, 04:256	*02:12, 02:49, 02:55:01-02:55:02, 02:115
5⁶	250 bp	1070 bp	*04:04:01-04:04:02, 04:06, 04:13, 04:34, 04:58, 04:122, 04:160, 04:178, 04:212	*01:22, 01:35, 02:03, 02:16:01-02:16:02, 02:18, 05:11, 05:17, 05:27, 05:68, 05:79, 05:115, 05:134, 06:04:01-06:04:02, 06:118, 06:153, 08:01:01-08:01:19, 08:03:01-08:04:03, 08:06, 08:08:01-08:11, 08:13-08:14, 08:16:01-08:16:02, 08:20-08:22, 08:24, 08:26N, 08:36N, 08:38-08:42, 08:44, 08:46, 08:50, 08:54, 08:56-08:61, 08:65-08:66, 08:72:01-08:72:02, 08:78-08:89N, 08:91, 08:93, 08:95-08:99, 08:101-08:102, 08:104-08:106, 08:109, 08:113, 08:117, 08:119, 08:121N-08:122, 08:124, 08:127N-08:131, 08:133, 08:135-08:139, 08:141Q, 08:143, 12:14:01-12:14:02, 12:18:01-12:18:02, 12:20, 12:83, 12:169, 12:175, 12:181, 14:06, 14:15, 14:53, 14:77, 15:02:01:01-15:07, 15:09-15:13, 15:15-15:19, 15:21-15:24, 15:26-15:50, 15:52-15:73, 15:76-15:83, 15:85-15:101, 15:103-15:133, 16:35, 16:40, 16:48, 17:01:01:02-17:16, 17:18-17:34
6⁴	95 bp 215 bp	1070 bp	*04:05 *04:112, 04:169	*14:73, 15:36
7⁵	145 bp	1070 bp	*04:07, 04:27, 04:32, 04:77, 04:89, 04:153	*03:34, 03:142, 03:261, 03:272, 05:78:01-05:78:02, 07:64, 07:402, 14:25, 15:36, 18:03, B*13:13:02
8	270 bp	1070 bp	*04:08, 04:34, 04:147, 04:212	*01:35, 01:107, 02:58, 05:27, 05:39, 06:96, 08:41, 08:115, 08:138, 12:83, 12:106, 12:122, 14:20, 15:15, 15:77, 17:07, 18:08

101.612-12 – including *Taq* pol., IFU-01
101.612-12u – without *Taq* pol., IFU-02

Visit www.olerup.com for
“Instructions for Use” (IFU)

Lot No.: **0F2**

Lot-specific information

9⁴	110 bp 180 bp 220 bp	800 bp	*04:35 *04:30 *04:09N	
10	190 bp 220 bp	1070 bp	*04:31, 04:91 *04:10-04:11, 04:36, 04:55, 04:153, 04:169, 04:210, 04:214-04:215N	*03:231, 05:78:01-05:78:02, 15:36
11⁶	180 bp	1070 bp	*04:01:01:01-04:01:09, 04:01:11-04:01:22, 04:01:24- 04:01:76, 04:01:79-04:01:81, 04:03:01-04:10, 04:12-04:20, 04:23-04:26, 04:28-04:32, 04:34-04:51, 04:53-04:54, 04:56-04:106, 04:108- 04:115N, 04:117-04:129, 04:131-04:168, 04:170N- 04:171, 04:173N-04:230, 04:232-04:257	*02:49, 02:75, 02:115, 05:25, 05:42, 06:05, 06:76:02, 07:02:09, 08:28, 08:137, 12:28, 12:132, 12:135, 12:146, 15:25, 15:62, 16:26, 16:46, 16:55, 16:64
12⁴	125 bp 165 bp	1070 bp	*04:11, 04:29, 04:36, 04:55, 04:172, 04:214 ^w *04:11, 04:33, 04:169, 04:172	*03:231, 03:248, 07:125, 07:356, 07:531, 12:194, 16:62, B*07:267 *02:104, 03:248, 05:141, 12:194, 15:100, 16:62, B*07:267
13	120 bp 215 bp 270 bp	1070 bp	*04:255N *04:12, 04:132 *04:52, 04:55	*03:231
14	155 bp 185 bp	1070 bp	*04:16, 04:163, 04:223:01- 04:223:02 *04:18	*02:104, 03:248, 05:64:01-05:64:02, 08:19, 15:100, A*24:52
15⁶	170 bp	1070 bp	*04:14, 04:68	*05:112, 16:45, A*24:96, A*24:146
16^{4,7}	85 bp 130 bp	1070 bp	*04:123N *04:15:01, 04:15:03, 04:37	*18:07N *03:05, 03:13:02, 03:25, 03:27, 03:35:02, 03:135, 03:167, 03:296, 03:302, 14:09, 14:45, B*15:78:03
17	245 bp 320 bp	1070 bp	*04:234N *04:17, 04:80, 04:100	*01:50, 14:54
18⁴	125 bp 220 bp	1070 bp	*04:70 *04:19, 04:94:01-04:94:02	*06:101, 12:10:01-12:10:02, 18:03, B*15:27:01-15:27:03, B*15:109, B*15:327, B*15:344, B*15:398
19^{4,6}	120 bp 150 bp 430 bp	1070 bp	*04:35, 04:37 *04:20, 04:40, 04:242 *04:238	*03:302, 14:45 *03:135
20	165 bp 250 bp 545 bp	1070 bp	*04:44 *04:47, 04:170N, 04:209 *04:15:02, 04:17, 04:100, 04:178, 04:224, 04:230, 04:242	*03:231, 05:78:01-05:78:02, 15:36, A*01:118, A*02:109, A*33:52
21⁴	85 bp 145 bp 240 bp	800 bp	*04:23, 04:108, 04:218 *04:38 *04:39, 04:121	
22⁴	120 bp 170 bp 360 bp	1070 bp	*04:24, 04:139, 04:140, 04:166, 04:420 *04:26 *04:226	*07:125, 07:356, 07:531 *02:104, 15:100
23⁴	85 bp	1070 bp	*04:25	

101.612-12 – including *Taq* pol., IFU-01
101.612-12u – without *Taq* pol., IFU-02

Visit www.olerup.com for
“Instructions for Use” (IFU)

Lot No.: **0F2**

Lot-specific information

	215 bp 235 bp		*04:41 *04:144	*03:171, 03:211:01, 05:93, 06:73, 08:20, 08:40, 12:109
24⁵	130 bp 170 bp	1070 bp	*04:24 *04:30, 04:42:01-04:42:02, 04:220	*07:125, 07:356, 07:531
25	160 bp 200 bp	1070 bp	*04:163 *04:43, 04:94:01-04:94:02, 04:171	A*24:52 *06:101, 12:10:01-12:10:02, 18:03, B*15:27:01-15:27:03, B*15:109, B*15:327, B*15:344, B*15:398
26⁶	210 bp 245 bp	800 bp	*04:45, 04:86 *04:250	
27^{4,9}	125 bp 255 bp 280 bp	800 bp	*04:50 *04:204 *04:46, 04:120	*05:64:01-05:64:02, 08:19, 08:101, 08:143
28^{4,8}	120 bp 160 bp 215 bp 255 bp	1070 bp	*04:75 *04:223:01-04:223:02 *04:48 *04:204	*05:64:01-05:64:02, 08:19
29⁴	105 bp 195 bp 245 bp	1070 bp	*04:82, 04:159 *04:49, 04:132 *04:170N, 04:249	
30⁴	75 bp 125 bp	1070 bp	*04:53 *04:234N	*05:49, B*07:90 *06:152N
31⁵	130 bp 170 bp 360 bp	1070 bp	*04:95N, 04:139 *04:51, 04:145 *04:226	*02:104, 15:100
32⁴	105 bp 235 bp 275 bp	1070 bp	*04:78, 04:141 *04:59Q, 04:121 *04:77	B*40:100
33⁴	90 bp 180 bp	1070 bp	*04:72, 04:218 *04:58, 04:65, 04:160, 04:203N	*07:08, 07:108:01-07:108:02, B*40:100
34⁴	75 bp 200 bp 270 bp	1070 bp	*04:96 *04:13, 04:58, 04:61, 04:68, 04:160, 04:253N *04:120, 04:201	*07:08, 07:108:01-07:108:02, 08:101, 08:143, B*47:09 *05:64:01-05:64:02, 08:19, 08:101, 08:143
35⁴	85 bp 120 bp 145 bp 175 bp	1070 bp	*04:62 *04:255N *04:115N *04:76, 04:137	
36^{4,5}	115 bp 150 bp	800 bp	*04:57 *04:63, 04:117	
37⁴	110 bp 135 bp	1070 bp	*04:63, 04:73 *04:74, 04:125	
38^{4,5}	95 bp 140 bp	800 bp	*04:83, 04:123N *04:74, 04:117	*03:232, 18:07N
39⁴	110 bp 140 bp 330 bp	1070 bp	*04:113 *04:71, 04:95N *04:79	*14:71 *01:02:34, 01:21
40	140 bp 205 bp 265 bp	800 bp	*04:56 *04:86 *04:64:01-04:64:02, 04:201	

101.612-12 – including *Taq* pol., IFU-01

101.612-12u – without *Taq* pol., IFU-02

Visit www.olerup.com for
“Instructions for Use” (IFU)

Lot No.: **0F2**

Lot-specific information

41⁵	135 bp 165 bp 280 bp	1070 bp	*04:105N *04:131 *04:54	*01:04, 01:54, 01:97, 01:102, 14:02:01:01-14:24:01, 14:25, 14:27-14:53, 14:56-14:78, 14:80-14:81
42⁴	95 bp	1070 bp	*04:69, 04:82, 04:159	*02:79, 16:12
43⁶	170 bp 255 bp	1070 bp	*04:81, 04:137 *04:88N, 04:209	
44⁴	90 bp 115 bp 140 bp	1070 bp	*04:108, 04:202 *04:254 *04:40, 04:60, 04:125, 04:242	*03:81, 03:175, 03:199, 03:245, 03:317, 14:24:01, B*15:78:03
45	130 bp 165 bp	1070 bp	*04:66, 04:233N *04:16, 04:26, 04:103, 04:145	*02:104, 03:248, 05:141, 12:194, 15:100, 16:62
46⁴	125 bp 160 bp 190 bp 300 bp	1070 bp	*04:93N, 04:254 *04:205N, 04:131 *04:187, 06:135 *04:67	*06:128N
47^{4,6}	50 bp 295 bp	800 bp	*04:114 *04:146, 04:161	*01:59, 01:118, 02:65, 03:130, 03:140, 03:243, 05:20, 06:82, 07:49, 07:210, 07:238, 07:247, 07:403, 12:54, 12:188, 14:04, 14:64, 14:77, 15:85, 16:57, A*68:46, B*07:253 *15:97, 03:205 ^w
48	390 bp 415 bp	1070 bp	*04:195 *04:84	*03:206, 03:212, 08:128
49	190 bp	1070 bp	*04:91, 04:173N, 04:225N	
50	295 bp 335 bp	1070 bp	*04:161 *04:162	*03:205 ^w
51	390 bp	1070 bp	*04:195	
52⁴	110 bp 185 bp 240 bp	1070 bp	*04:150 *04:203N *04:155	
53	335 bp	800 bp	*04:106	*03:236, 08:78
54	140 bp 235 bp	1070 bp	*04:115N, 04:219 *04:249	
55	190 bp 245 bp	1070 bp	*04:191N, 04:215N, 04:225N *04:250	
56	425 bp 470 bp	1070 bp	*04:28 *04:144	*03:171, 03:211:01, 05:93, 06:73, 08:20, 08:40, 12:109
57	150 bp 245 bp	1070 bp	*04:205N *04:182, 04:233N	*06:128N *06:78, 07:309
58	170 bp 275 bp	1070 bp	*04:217N *04:196	
59⁴	95 bp	800 bp	*04:202, 04:207	*14:24:01
60	130 bp	1070 bp	*04:01:01:01-04:01:04, 04:01:06, 04:01:08, 04:01:10-04:01:23, 04:01:25- 04:01:32, 04:01:34-04:01:61,	*14:28:02, 18:01-18:10

101.612-12 – including *Taq* pol., IFU-01

101.612-12u – without *Taq* pol., IFU-02

Visit www.olerup.com for
“Instructions for Use” (IFU)

Lot No.: **0F2**

Lot-specific information

			04:01:63-04:01:74, 04:01:76, 04:01:79-04:01:81, 04:03:01- 04:04:01, 04:05-04:14, 04:16, 04:18-04:20, 04:23- 04:36, 04:38-04:39, 04:41- 04:59Q, 04:61-04:79, 04:81- 04:94:01, 04:95N-04:99, 04:101-04:109, 04:111- 04:159, 04:161-04:177, 04:179, 04:181-04:221, 04:223:02, 04:225N-04:229, 04:231-04:239, 04:241, 04:243-04:257	
61	160 bp 285 bp	1070 bp	*04:236N *04:206	*07:246:02, A*11:92
62⁴	105 bp 205 bp	1070 bp	*04:141 *04:253N	
63	175 bp	1070 bp	*04:180:01-04:180:02	*01:32:01, 01:32:02 ^w , 02:56, 06:20, 08:123, 08:139, 15:126, 16:98, B*58:02:01^w
64¹⁰	-	-	Negative Control	

¹Alleles are assigned by the presence of specific PCR product(s). However, the sizes of the specific PCR products may be helpful in the interpretation of HLA-C*04 SSP typings.

When the primers in a primer mix can give rise to HLA-specific PCR products of more than one length this is indicated if the size difference is more than 20 base pairs. Size differences of 20 base pairs or less are not given. For high resolution SSP kits, the alleles listed are specified according to amplicon length.

Nonspecific amplifications, i.e. a ladder or a smear of bands, may sometimes be seen. GC-rich primers have a higher tendency of giving rise to nonspecific amplifications than other primers.

PCR fragments longer than the control bands may sometimes be observed. Such bands should be disregarded and do not influence the interpretation of the SSP typings.

PCR fragments migrating faster than the control bands, but slower than a 400 bp fragment may be seen in some gel read-outs. Such bands can be disregarded and do not influence the interpretation of the SSP typings.

Some primers may give rise to primer oligomer artifacts. Sometimes this phenomenon is an inherent feature of the primer pair(s) of a primer mix. More often it is due to other factors such as too low amount of DNA in the PCR reactions, taking too long time in setting up the PCR reactions, working at elevated room temperature or using thermal cyclers that are not pre-heated.

²The internal positive control primer pairs amplify segments of the human growth hormone gene. The internal positive control bands are 1070 or 800 base pairs respectively, well distribution as outlined in the table. Well number 1 contains the shorter, 800 bp, internal positive control band. The well distribution of the internal controls can help in orientation of the kit on gel photo, as well as allow for kit identification. In the presence of a specific amplification the intensity of the control band often decreases.

³For several HLA Class I alleles 1st and/or 4th exon(s) and beyond, as well as intron nucleotide sequences, are not available. In these instances it is not known whether some of the primers of the SSP sets are completely matched with the target sequences or not. Assumption is made that unknown sequences in these regions are conserved within allelic groups.

⁴HLA-specific PCR products shorter than 125 base pairs have a lower intensity and are less sharp than longer PCR products.

⁵Primer mixes 7, 24, 31, 36, 38 and 41 have a tendency to giving rise to primer oligomer formation.

⁶Primer mixes 5, 11, 15, 19, 26, 43 and 47 may have tendencies of unspecific amplification, most pronounced in primer mix 15.

⁷Primer mix 16 may give rise to a lower yield of HLA-specific PCR product than the other C*04 primer mixes.

101.612-12 – including *Taq* pol., IFU-01
101.612-12u – without *Taq* pol., IFU-02

Visit www.olerup.com for
“Instructions for Use” (IFU)

Lot No.: 0F2

Lot-specific information

⁸Primer mix 28 may give rise to a long unspecific amplification product of approximately 500 bp. This should be disregarded when interpreting the C*04 typings.

⁹In primer mix 27 the positive control band may be weaker than for other HLA-C*04 primer mixes.

¹⁰Primer mix 64 contains a negative control, which will amplify more than 95% of HLA amplicons as well as the amplicons generated by the control primer pairs matching the human growth hormone gene. HLA-specific PCR product sizes range from 75 to 200 base pairs and the PCR product generated by the HGH positive control primer pair is 430 base pairs.

'w', may be weakly amplified.

101.612-12 – including *Taq* pol., IFU-01
101.612-12u – without *Taq* pol., IFU-02

Visit www.olerup.com for
“Instructions for Use” (IFU)

Lot No.: **0F2**

Lot-specific information
PRIMER SPECIFICATION

Well No.	1	2	3	4	5	6	7	8	9	10	11	12
Length of spec. PCR product	250	220	150	210	250	95	145	270	110	190	180	125
						215			180	220		165
									220			
Length of int. pos. control ¹	800	1070	1070	1070	1070	1070	1070	1070	800	1070	1070	1070
5'-primer(s) ²	2 nd I	108	108	118	2 nd I	98	112	2 nd I	391	112	201	218
	5'-CCA 3'	5'-gTT 3'	5'-gTT 3'	5'-CCA 3'	5'-CCA 3'	5'-CTC 3'	5'-CCT 3'	5'-CCA 3'	5'-ACC 3'	5'-CCT 3'	5'-CCA 3'	5'-ggA 3'
		108	108				459		1018	368	201	
		5'-gTC 3'	5'-gTC 3'				5'-gAT 3'		5'-gTg 3'	5'-gTT 3'	5'-CCA 3'	
		112	112									
		5'-CCT 3'	5'-CCT 3'									
		112	112									
		5'-CTT 3'	5'-CTT 3'									
3'-primer(s) ³	539	289	218	289	539	154	218	559	459	262	341	302
	5'-TCC 3'	5'-AgC 3'	5'-gCT 3'	5'-AgC 3'	5'-TCA 3'	5'-CAg 3'	5'-gCg 3'	5'-CAg 3'	5'-AgA 3'	5'-Tgg 3'	5'-CgT 3'	5'-ggC 3'
		289	218	289		270	559		1052	289		341
		5'-AgC 3'	5'-gTT 3'	5'-AgC 3'		5'-TAG 3'	5'-CTC 3'		5'-Tgg 3'	5'-AgT 3'		5'-Cgg 3'
				291					1092	289		
				5'-TCg 3'					5'-TTA 3'	5'-AgT 3'		
										521		
										5'-ggA 3'		
Well No.	1	2	3	4	5	6	7	8	9	10	11	12

Well No.	13	14	15	16	17	18	19	20	21	22	23	24
Length of spec. PCR product	120	155	170	85	245	125	120	165	90	120	85	130
				130	320	220	150	250	145	170	215	170
							430	545	240	360	235	
Length of int. pos. control ¹	1070	1070	1070	1070	1070	1070	1070	1070	800	1070	1070	1070
5'-primer(s) ²	112	105	412	368	379	228	322	112	368	28	172	97
	5'-CCT 3'	5'-gCT 3'	5'-ATA 3'	5'-gTg 3'	5'-ACg 3'	5'-ATg 3'	5'-gCC 3'	5'-CCT 3'	5'-gTT 3'	5'-TCC 3'	5'-TCC 3'	5'-TCg 3'
		368		369	454	368	347			89	652	127
		5'-gTT 3'		5'-TAC 3'	5'-ACT 3'	5'-gTT 3'	5'-gTA 3'			5'-gAT 3'	5'-CCA 3'	5'-ggA 3'
				415			355			127	670	1018
				5'-ACT 3'			5'-CCT 3'			5'-ggA 3'	5'-CCg 3'	5'-gTg 3'
							368			133		
							5'-gTg 3'			5'-CCT 3'		
							391			142		
							5'-ACC 3'			5'-TCT 3'		
3'-primer(s) ³	193	218	539	459	3 rd I	312	459	238	412	218	218	218
	5'-CgC 3'	5'-gCT 3'	5'-TCT 3'	5'-AgA 3'	5'-ACg 3'	5'-AgT 3'	5'-AgA 3'	5'-CCA 3'	5'-gTC 3'	5'-gCT 3'	5'-gCT 3'	5'-gCT 3'
		278	485			538		319	420		846	1052
	5'-ggA 3'	5'-CCA 3'				5'-CCA 3'		5'-gCT 3'	5'-gCC 3'		5'-CAC 3'	5'-Tgg 3'
		295	485			550		319	472			
	5'-TCC 3'	5'-CCT 3'				5'-CAT 3'		5'-gCA 3'	5'-ggC 3'			
		343	514					327	568			
	5'-T 3'	5'-CTT 3'						5'-TTT 3'	5'-CTg 3'			
								368	569			
								5'-CAT 3'	5'-ACA 3'			
Well No.	13	14	15	16	17	18	19	20	21	22	23	24

101.612-12 – including *Taq* pol., IFU-01
101.612-12u – without *Taq* pol., IFU-02

Visit www.olerup.com for
“Instructions for Use” (IFU)

Lot No.: 0F2

Lot-specific information

Well No.	25	26	27	28	29	30	31	32	33	34	35	36
Length of spec. PCR product	160	210	125	120	105	75	130	105	90	75	85	115
			280	215	245		360	275		270	145	
				255							175	
Length of int. pos. control ¹	1070	800	800	1070	1070	1070	1070	1070	1070	1070	1070	800
5'-primer(s) ²	368	112	368	232	112	454	28	368	368	368	112	350
	5'-gTT 3'	5'-CCT 3'	5'-gTT 3'	5'-Agg 3'	5'-CCT 3'	5'-ACT 3'	5'-TCC 3'	5'-gTT 3'	5'-gTT 3'	5'-gTT 3'	5'-CCT 3'	5'-TCT 3'
				368	900	503	81					383
				5'-gTT 3'	5'-CCg 3'	5'-CCg 3'	5'-CAg 3'					5'-ggC 3'
							89					386
							5'-gAC 3'					5'-gCA 3'
							133					
							5'-CCT 3'					
							459					
							5'-gAT 3'					
3'-primer(s) ³	485	277	454	312	256	539	218	430	407	403	154	459
	5'-CCA 3'	5'-gCT 3'	5'-CTg 3'	5'-AgT 3'	5'-CCA 3'	5'-TCC 3'	5'-gCT 3'	5'-gCA 3'	5'-ACg 3'	5'-gCA 3'	5'-CAT 3'	5'-AgA 3'
	518	284	581	485	278		549	430	420	527	193	
	5'-CCA 3'	5'-gTA 3'	5'-ATg 3'	5'-CCT 3'	5'-ggA 3'		5'-AgT 3'	5'-gCT 3'	5'-gCC 3'	5'-CCg 3'	5'-CgC 3'	
	538	314	601	544	308			563	505	532	217	
	5'-CCA 3'	5'-gCT 3'	5'-CTT 3'	5'-ggg 3'	5'-TCT 3'			5'-CgT 3'	5'-gCT 3'	5'-CTA 3'	5'-CTA 3'	
			613	581	327			569	512	589	242	
			5'-gCA 3'	5'-ATg 3'	5'-TTT 3'			5'-ACA 3'	5'-CCA 3'	5'-CTT 3'	5'-CCC 3'	
					963			603	513	601	247	
					5'-gCT 3'			5'-TTg 3'	5'-TCT 3'	5'-CTT 3'	5'-ATT 3'	
Well No.	25	26	27	28	29	30	31	32	33	34	35	36

Well No.	37	38	39	40	41	42	43	44	45	46	47	48
Length of spec. PCR product	110	95	110	140	135	95	170	90	130	125	50	390
			330	265	280			140		160		
										300		
Length of int. pos. control ¹	1070	800	1070	800	1070	1070	1070	1070	1070	1070	800	1070
5'-primer(s) ²	364	350	98	112	215	256	112	355	89	83	302	704
	5'-ggT 3'	5'-TCT 3'	5'-CTT 3'	5'-CCT 3'	5'-gCA 3'	5'-ACg 3'	5'-CCT 3'	5'-CCT 3'	5'-gAC 3'	5'-CTA 3'	5'-gAA 3'	5'-TgT 3'
	371	364	459	368	249	900		364	89	190	3 ^d	731
	5'-TgA 3'	5'-ggT 3'	5'-gAT 3'	5'-gTT 3'	5'-TAG 3'	5'-CCg 3'		5'-ggg 3'	5'-gAT 3'	5'-ACT 3'	5'-Cgg 3'	5'-ggg 3'
	386	395	3 ^d		419			371	98	215		
	5'-gCA 3'	5'-gCT 3'	5'-Cgg 3'		5'-gTC 3'			5'-TgA 3'	5'-CTA 3'	5'-gCA 3'		
	392	415						386	124	232		
	5'-CgC 3'	5'-ACT 3'						5'-gCT 3'	5'-gCT 3'	5'-AgT 3'		
								406	127	375		
								5'-gCC 3'	5'-ggT 3'	5'-TgA 3'		
								409		386		
								5'-ggC 3'		5'-gCT 3'		
3'-primer(s) ³	459	459	201	212	341	302	239	459	218	341	312	956
	5'-AgA 3'	5'-AgA 3'	5'-CTT 3'	5'-gCC 3'	5'-CgT 3'	5'-ggT 3'	5'-gCT 3'	5'-AgA 3'	5'-gCT 3'	5'-CgT 3'	5'-Agg 3'	5'-CAg 3'
			527	277	3 ^d	963	242			459	845	
			5'-CCA 3'	5'-gCT 3'	5'-ACg 3'	5'-gCT 3'	5'-CCC 3'			5'-AgA 3'	5'-ACA 3'	
			549	589			319				845	
			5'-AgT 3'	5'-CTT 3'			5'-gCA 3'				5'-ACT 3'	
			878	595			331					
			5'-ggA 3'	5'-CCg 3'			5'-CTA 3'					
				595								
				5'-CCT 3'								
Well No.	37	38	39	40	41	42	43	44	45	46	47	48

101.612-12 – including *Taq* pol., IFU-01
101.612-12u – without *Taq* pol., IFU-02

Visit www.olerup.com for
“Instructions for Use” (IFU)

Lot No.: **0F2**

Lot-specific information

Well No.	49	50	51	52	53	54	55	56	57	58	59	60
Length of spec. PCR product	190	295	260	110	335	140	190	425	150	170	95	130
		335	390	185		235	245	470	245	275		
				240								
Length of int. pos. control ¹	1070	1070	1070	1070	800	1070	1070	1070	1070	1070	800	1070
5'-primer(s) ²	112	3 rd I	731	368	787	112	112	652	127	109	400	368
	5'-CCT 3'	5'-Cgg 3'	5'-ggg 3'	5'-gTT 3'	5'-ATA 3'	5'-CCT 3'	5'-CCT 3'	5'-CCA 3'	5'-ggT 3'	5'-TgA 3'	5'-TCA 3'	5'-gTT 3'
			862					697	149	210	406	
			5'-ACA 3'					5'-TCC 3'	5'-ggA 3'	5'-Ag 3'	5'-gCC 3'	
								232				
								5'-AgT 3'				
3'-primer(s) ³	262	845	956	435	956	212	251	956	341	341	459	459
	5'-Tgg 3'	5'-ACT 3'	5'-CAg 3'	5'-TCA 3'	5'-CAg 3'	5'-gCA 3'	5'-CCT 3'	5'-CAg 3'	5'-CgT 3'	5'-CgT 3'	5'-AgA 3'	5'-AgA 3'
	265	883		513		217	265					
	5'-CTA 3'	5'-ggC 3'		5'-TCT 3'		5'-CTA 3'	5'-CTA 3'					
	268			565		308	273					
	5'-CTA 3'			5'-CAT 3'		5'-TCT 3'	5'-TTC 3'					
							314					
							5'-gCT 3'					
Well No.	49	50	51	52	53	54	55	56	57	58	59	60

Well No.	61	62	63
Length of spec. PCR product	160	105	175
	285	205	
Length of int. pos. control ¹	1070	1070	1070
5'-primer(s) ²	96	368	2 nd I
	5'-TTg 3'	5'-gTT 3'	5'-CCA 3'
	220		
	5'-gC 3'		
3'-primer(s) ³	341	430	463
	5'-CgT 3'	5'-gCT 3'	5'-gCT 3'
		532	
		5'-CTA 3'	
Well No.	61	62	63

¹The internal positive control primer pairs amplify segments of the human growth hormone gene. The internal positive control bands are 1070 or 800 base pairs respectively, well distribution as outlined in the table. Well number 1 contains the shorter, 800 bp, internal positive control band. The well distribution of the internal controls can help in orientation of the kit on gel photo, as well as allow for kit identification. In the presence of a specific amplification the intensity of the control band often decreases.

²The nucleotide position matching the specificity-determining 3'-end of the primer is given. Nucleotide numbering as on the www.ebi.ac.uk/imgt/hla web site. The sequence of the 3 terminal nucleotides of the primer is given.

³The nucleotide position matching the specificity-determining 3'-end of the primer is given in the anti-sense direction. Nucleotide numbering as on the www.ebi.ac.uk/imgt/hla web site. The sequence of the 3 terminal nucleotides of the primer is given.

101.612-12 – including *Taq* pol., IFU-01
101.612-12u – without *Taq* pol., IFU-02

Visit www.olerup.com for
“Instructions for Use” (IFU)

Lot No.: **0F2**

Lot-specific information

CELL LINE VALIDATION SHEET																				
HLA-C*04 SSP subtyping kit²																				
				Well																
				1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	
				Prod. No.:	201778201	201778202	201778203	201778204	201778205	201778206	201778207	201778208	201778209	201778210	201778211	201778212	201778213	201778214	201778215	201778216
IHWC cell line ¹		C*																		
1	9001	SA	*07:02	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
2	9280	LK707	*07:01	*15:05	-	-	-	-	+	-	-	-	-	-	-	-	-	-	-	-
3	9011	E4181324	*12:02		+	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
4	9275	GU373	*03:04	*04:01	+	+	+	-	-	-	-	-	-	-	+	-	-	-	-	-
5	9009	KAS011	*06:02		+	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
6	9353	SM	*03:04	*07:02	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
7	9020	QBL	*05:01		+	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
8	9025	DEU	*04:01		+	+	+	-	-	-	-	-	-	-	+	-	-	-	-	-
9	9026	YAR	*12:03		+	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
10	9107	LKT3	*01:02		+	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
11	9051	PITOUT	*16:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
12	9052	DBB	*06:02		+	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
13	9004	JESTHOM	*01:02		+	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
14	9071	OLGA	*01:02	*03:04	+	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
15	9075	DKB	*03:04		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
16	9037	SWEIG007	*02:02		+	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
17	9282	CTM3953540	*03:03	*07:01	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
18	9257	32367	*01:02	*07:05	+	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
19	9038	BM16	*07:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
20	9059	SLE005	*03:04		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
21	9064	AMALA	*03:03		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
22	9056	KOSE	*12:03		+	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
23	9124	IHL	*01:02	*15:02	+	-	-	-	+	-	-	-	-	-	-	-	-	-	-	-
24	9035	JBUSH	*12:03		+	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
25	9049	IBW9	*08:02		+	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
26	9285	WT49	*07:18		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
27	9191	CH1007	*07:04	*15:29	-	-	-	-	+	-	-	-	-	-	-	-	-	-	-	-
28	9320	BEL5GB	*05:01	*16:01	+	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
29	9050	MOU	*16:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
30	9021	RSH	*17:01		-	-	-	-	+	-	-	-	-	-	-	-	-	-	-	-
31	9019	DUCAF	*05:01		+	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
32	9297	HAG	*17:03		-	-	-	-	+	-	-	-	-	-	-	-	-	-	-	-
33	9098	MT14B	*03:04		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
34	9104	DHIF	*12:03		+	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
35	9302	SSTO	*05:01		+	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
36	9024	KT17	*03:03	*04:01	+	+	+	-	-	-	-	-	-	-	+	-	-	-	-	-
37	9065	HHKB	*07:02		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
38	9099	LZL	*03:03		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
39	9315	CML	*02:02	*07:01	+	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
40	9134	WHONP199	*01:02	*06:02	+	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
41	9055	H0301	*08:02		+	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
42	9066	TAB089	*01:02		+	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
43	9076	T7526	*01:02	*08:01	+	-	-	-	+	-	-	-	-	-	-	-	-	-	-	-
44	9057	TEM	*12:03		+	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
45	9239	SHJO	*06:02	*17:01	+	-	-	-	+	-	-	-	-	-	-	-	-	-	-	-
46	9013	SCHU	*07:02		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
47	9045	TUBO	*07:04	*15:02	-	-	-	-	+	-	-	-	-	-	-	-	-	-	-	-
48	9303	TER-ND	*04:01	*16:01	+	+	+	-	-	-	-	-	-	-	+	-	-	-	-	-



101.612-12 – including *Taq* pol., IFU-01
101.612-12u – without *Taq* pol., IFU-02

Visit www.olerup.com for
“Instructions for Use” (IFU)

Lot No.: **0F2**

Lot-specific information

CELL LINE VALIDATION SHEET				HLA-C*04 SSP subtyping kit ²																
				Well																
				17	18	19	20	21	22	23	24	25	26	27	28	29	30	31	32	
				Prod. No.:	201778217	201778218	201778219	201778220	201778221	201778222	201778223	201778224	201778225	201778226	201778227	201778228	201778229	201778230	201778231	201778232
	IHWC cell line ¹		C*																	
1	9001 SA		*07:02	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
2	9280 LK707		*07:01 *15:05	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
3	9011 E4181324		*12:02	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
4	9275 GU373		*03:04 *04:01	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
5	9009 KAS011		*06:02	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
6	9353 SM		*03:04 *07:02	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
7	9020 QBL		*05:01	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
8	9025 DEU		*04:01	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
9	9026 YAR		*12:03	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
10	9107 LKT3		*01:02	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
11	9051 PITOUT		*16:01	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
12	9052 DBB		*06:02	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
13	9004 JESTHOM		*01:02	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
14	9071 OLGA		*01:02 *03:04	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
15	9075 DKB		*03:04	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
16	9037 SWEIG007		*02:02	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
17	9282 CTM3953540		*03:03 *07:01	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
18	9257 32367		*01:02 *07:05	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
19	9038 BM16		*07:01	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
20	9059 SLE005		*03:04	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
21	9064 AMALA		*03:03	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
22	9056 KOSE		*12:03	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
23	9124 IHL		*01:02 *15:02	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
24	9035 JBUSH		*12:03	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
25	9049 IBW9		*08:02	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
26	9285 WT49		*07:18	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
27	9191 CH1007		*07:04 *15:29	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
28	9320 BEL5GB		*05:01 *16:01	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
29	9050 MOU		*16:01	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
30	9021 RSH		*17:01	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
31	9019 DUCAF		*05:01	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
32	9297 HAG		*17:03	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
33	9098 MT14B		*03:04	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
34	9104 DHIF		*12:03	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
35	9302 SSTO		*05:01	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
36	9024 KT17		*03:03 *04:01	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
37	9065 HHKB		*07:02	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
38	9099 LZL		*03:03	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
39	9315 CML		*02:02 *07:01	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
40	9134 WHONP199		*01:02 *06:02	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
41	9055 H0301		*08:02	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
42	9066 TAB089		*01:02	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
43	9076 T7526		*01:02 *08:01	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
44	9057 TEM		*12:03	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
45	9239 SHJO		*06:02 *17:01	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
46	9013 SCHU		*07:02	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
47	9045 TUBO		*07:04 *15:02	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
48	9303 TER-ND		*04:01 *16:01	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	

101.612-12 – including *Taq* pol., IFU-01
101.612-12u – without *Taq* pol., IFU-02

Visit www.olerup.com for
“Instructions for Use” (IFU)

Lot No.: **0F2**

Lot-specific information

CELL LINE VALIDATION SHEET																				
HLA-C*04 SSP subtyping kit²																				
				Well																
				33	34	35	36	37	38	39	40	41	42	43	44	45	46	47	48	
				Prod. No.:	201778233	201778234	201778235	201778236	201778237	201778238	201778239	201778240	201778241	201778242	201778243	201778244	201778245	201778246	201778247	201778248
	IHWC cell line ¹		C*																	
1	9001 SA		*07:02		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
2	9280 LK707		*07:01	*15:05	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
3	9011 E4181324		*12:02		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
4	9275 GU373		*03:04	*04:01	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
5	9009 KAS011		*06:02		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
6	9353 SM		*03:04	*07:02	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
7	9020 QBL		*05:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
8	9025 DEU		*04:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
9	9026 YAR		*12:03		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
10	9107 LKT3		*01:02		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
11	9051 PITOUT		*16:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
12	9052 DBB		*06:02		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
13	9004 JESTHOM		*01:02		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
14	9071 OLGA		*01:02	*03:04	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
15	9075 DKB		*03:04		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
16	9037 SWEIG007		*02:02		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
17	9282 CTM3953540		*03:03	*07:01	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
18	9257 32367		*01:02	*07:05	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
19	9038 BM16		*07:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
20	9059 SLE005		*03:04		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
21	9064 AMALA		*03:03		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
22	9056 KOSE		*12:03		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
23	9124 IHL		*01:02	*15:02	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
24	9035 JBUSH		*12:03		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
25	9049 IBW9		*08:02		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
26	9285 WT49		*07:18		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
27	9191 CH1007		*07:04	*15:29	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
28	9320 BEL5GB		*05:01	*16:01	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
29	9050 MOU		*16:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
30	9021 RSH		*17:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
31	9019 DUCAF		*05:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
32	9297 HAG		*17:03		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
33	9098 MT14B		*03:04		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
34	9104 DHIF		*12:03		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
35	9302 SSTO		*05:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
36	9024 KT17		*03:03	*04:01	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
37	9065 HHKB		*07:02		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
38	9099 LZL		*03:03		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
39	9315 CML		*02:02	*07:01	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
40	9134 WHONP199		*01:02	*06:02	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
41	9055 H0301		*08:02		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
42	9066 TAB089		*01:02		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
43	9076 T7526		*01:02	*08:01	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
44	9057 TEM		*12:03		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
45	9239 SHJO		*06:02	*17:01	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
46	9013 SCHU		*07:02		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
47	9045 TUBO		*07:04	*15:02	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
48	9303 TER-ND		*04:01	*16:01	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

101.612-12 – including *Taq* pol., IFU-01
101.612-12u – without *Taq* pol., IFU-02

Visit www.olerup.com for
“Instructions for Use” (IFU)

Lot No.: **0F2**

Lot-specific information

CELL LINE VALIDATION SHEET					HLA-C*04 SSP subtyping kit ²															
					Well															
					49	50	51	52	53	54	55	56	57	58	59	60	61	62	63	
					Prod. No.:	201778249	201778250	201778251	201778252	201778253	201778254	201778255	201778256	201778257	201778258	201778259	201778260	201778261	201778262	201778263
IHWK cell line ¹			C*																	
1	9001	SA	*07:02		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
2	9280	LK707	*07:01	*15:05	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
3	9011	E4181324	*12:02		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
4	9275	GU373	*03:04	*04:01	-	-	-	-	-	-	-	-	-	-	-	+	-	-	-	
5	9009	KAS011	*06:02		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
6	9353	SM	*03:04	*07:02	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
7	9020	QBL	*05:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
8	9025	DEU	*04:01		-	-	-	-	-	-	-	-	-	-	-	+	-	-	-	
9	9026	YAR	*12:03		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
10	9107	LKT3	*01:02		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
11	9051	PITOUT	*16:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
12	9052	DBB	*06:02		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
13	9004	JESTHOM	*01:02		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
14	9071	OLGA	*01:02	*03:04	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
15	9075	DKB	*03:04		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
16	9037	SWEIG007	*02:02		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
17	9282	CTM3953540	*03:03	*07:01	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
18	9257	32367	*01:02	*07:05	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
19	9038	BM16	*07:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
20	9059	SLE005	*03:04		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
21	9064	AMALA	*03:03		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
22	9056	KOSE	*12:03		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
23	9124	IHL	*01:02	*15:02	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
24	9035	JBUSH	*12:03		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
25	9049	IBW9	*08:02		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
26	9285	WT49	*07:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
27	9191	CH1007	*07:04	*15:05	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
28	9320	BEL5GB	*05:01	*16:01	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
29	9050	MOU	*16:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
30	9021	RSH	*17:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
31	9019	DUCAF	*05:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
32	9297	HAG	*17:01	*17:03	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
33	9098	MT14B	*03:04		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
34	9104	DHIF	*12:03		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
35	9302	SSTO	*05:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
36	9024	KT17	*03:03	*04:01	-	-	-	-	-	-	-	-	-	-	-	+	-	-	-	
37	9065	HHKB	*07:02		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
38	9099	LZL	*03:03		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
39	9315	CML	*02:02	*07:01	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
40	9134	WHONP199	*01:02	*06:02	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
41	9055	H0301	*08:02		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
42	9066	TAB089	*01:02		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
43	9076	T7526	*01:02	*08:01	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
44	9057	TEM	*12:03		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
45	9239	SHJO	*06:02	*17:01	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
46	9013	SCHU	*07:02		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
47	9045	TUBO	*07:04	*15:02	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
48	9303	TER-ND	*04:01	*16:01	-	-	-	-	-	-	-	-	-	-	-	+	-	-	-	

101.612-12 – including Taq pol., IFU-01
101.612-12u – without Taq pol., IFU-02

Visit www.olerup.com for
“Instructions for Use” (IFU)

Lot No.: 0F2

Lot-specific information

¹The provided cell line HLA specificities are retrieved from the <http://www.ihwg.org/hla> web site. The specificity of an individual cell line may thus be subject to change.

²The specificity of each primer solution in the kit has been tested against 48 well characterized cell line DNAs and where applicable, additional cell line DNAs.

No DNAs carrying the alleles to be amplified by primer solutions 6, 8, 10, 12 to 15, 17, 19 to 24, 26 to 40, 42 to 59 and 61 to 63 were available.

The specificity of the primers in primer solutions 6, 8, 10, 12 to 15, 17, 19 to 22, 24, 27, 28, 31 to 34, 39, 42, 44, 45, 47, 53 and 63 were tested by separately adding one or more additional 5'-primers, respectively one or more additional 3'-primers.

In primer solutions 26, 29, 35, 40, 43, 49, 50, 52, 54, 55 and 62 it was only possible to test the 5'-primers, the 3'-primers were not possible to test.

In primer solutions 23, 30, 36 to 38, 46, 48, 51, 56 to 59 and 61 it was only possible to test the 3'-primers, the 5'-primers were not possible to test.

In primer solutions 2, 3, 9, 11, 16 to 19, 22, 24, 28, 31, 41, 44 and 45 one or more of the 5'-primers were not possible to test, and in primer solutions 3, 4, 6, 9, 10, 13, 14, 18, 20, 21, 24, 25, 27, 28, 31 to 34, 39, 42 and 47 one to four of the 3'-primers were not possible to test.

Additional primers in primer solutions 7, 9, 16, 18, 25 and 41 were tested by separately adding one 5'-primer and/or one 3'-primer.

101.612-12 – including *Taq* pol., IFU-01
101.612-12u – without *Taq* pol., IFU-02

Visit www.olerup.com for
“Instructions for Use” (IFU)

Lot No.: **0F2**

Lot-specific information

ADDRESSES:

Manufacturer:

Olerup SSP AB, Franzengatan 5, SE-112 51 Stockholm, Sweden.

Tel: +46-8-717 88 27

Fax: +46-8-717 88 18

E-mail: olerup-se@caredx.com

Web page: <http://www.olerup.com>

Distributed by:

Olerup GmbH, Löwengasse 47 / 6, AT-1030 Vienna, Austria.

Tel: +43-1-710 15 00

Fax: +43-1-710 15 00 10

E-mail: olerup-at@caredx.com

Web page: <http://www.olerup.com>

Olerup Inc., 901 S. Bolmar St., Suite R, West Chester, PA 19382

Tel: 1-877-OLERUP1

Fax: 610-344-7989

E-mail: olerup-us@caredx.com

Web page: <http://www.olerup.com>

For information on *Olerup* distributors worldwide, contact **Olerup GmbH**.